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any antibiotics inhibit bacterial protein synthesis. Understanding how microbes become antibiotic resistant is
important both for developing effective treatment regimens and
designing new therapeutics. Macrolides consist of a 14- to
16-member lactone ring with different appended sugars and
comprise a key group of inhibitors of bacterial translation (1, 2).
The inhibitory activity of macrolides, including erythromycin,
depends on binding to a site near the polypeptide exit tunnel of
the large ribosomal subunit (3, 4). Because macrolides do not
bind to ribosomes with an occupied exit tunnel and cause the
synthesis of 2–10 residue peptides in translation assays in vitro,
it has been proposed that drug binding physically blocks elongation of nascent proteins beyond this size (5–7).
Some macrolide-resistance mutations alter the ribosomal target
site and prevent binding (4, 8). Intriguingly, other mutations confer
resistance despite the fact that macrolides still bind the mutant
ribosome well (8–10). For example, deletion of the M82K83R84
sequence in Escherichia coli ribosomal protein L22 (⌬MKR) allows
growth in the presence of high levels of erythromycin and other
macrolides (11–13). The same mutation makes Haemophilus influenzae resistant to numerous macrolides (14); different L22 mutations also confer macrolide resistance in other bacterial species (2).
When binding has been measured, ribosomes with macrolideresistant alterations in L22 bind erythromycin with near wild-type
affinity (8, 10, 12, 15).
In a crystal structure of the E. coli ribosome, the MKR sequence
is part of an extended L22 loop, which together with a similar loop
in protein L4 forms a narrow constriction in the exit tunnel (Fig. 1A)
(16, 17). Cryo-EM studies initially revealed a widened exit tunnel
in E. coli ⌬MKR ribosomes (18). This loop is also displaced to
create an expanded tunnel in structures of ⌬MKR ribosomes from
Thermus thermophilus and Haloarcula marismortui (4, 19). These
results explain the altered chemical reactivity in E. coli ⌬MKR
ribosomes of 23S-RNA bases (13). Together, these results support
a prevailing model in which the L22 ⌬MKR deletion confers
antibiotic resistance by allowing nascent proteins to enter the
ribosome exit tunnel despite bound macrolides (18, 19).
Here, we rule out the accepted model of L22-mediated macrolide
resistance by showing that E. coli ⌬MKR ribosomes are inhibited
www.pnas.org兾cgi兾doi兾10.1073兾pnas.0810357105

by erythromycin in vitro and in vivo. Instead, the ⌬MKR mutation
appears to reduce the intracellular concentration of macrolides. We
present evidence that links changes in the activity of the AcrABTolC efflux system to antibiotic resistance in the ⌬MKR strain and
suggest that changes in translation of specific proteins are responsible for ⌬MKR-linked macrolide resistance.
Results
⌬MKR Ribosomes Are Inhibited by Erythromycin in Vitro. The E. coli

S10 operon, encoding L22 and additional ribosomal proteins, can
be deleted without substantially altering the growth rate if the cells
contain a plasmid-borne operon encoding L22 or L22 fused to the
titin-I27 domain (20). The L22-titin fusions are longer than unmodified L22 and this feature allowed us to establish unambiguously that mutant forms of L22 were the only versions present in cell
(20). Using this system, we constructed a strain expressing only
L22-titin with the ⌬MKR mutation. We purified ribosomes from
strains expressing just L22-titin or just ⌬MKR-L22-titin; SDSPAGE of these ribosomes revealed that the ⌬MKR L22 variant had
a slightly faster electrophoretic mobility (Fig. 1B). In coupled
transcription/translation reactions, both types of ribosomes were
equally active in the synthesis of 14C-labeled test proteins (Fig. 1C
Left) and had activities comparable to ribosomes containing unfused L22 (data not shown). Surprisingly, however, increasing
concentrations of erythromycin inhibited the ⌬MKR-L22 ribosomes and the ‘‘wild-type’’ ribosomes (Fig. 1 C and D). Fitting these
data gave apparent inhibition constants (Ki) of 41 ⫾ 9 nM for the
L22-titin ribosomes and 26 ⫾ 5 nM for the ⌬MKR-L22-titin
ribosomes (Fig. 1D). The Ki values were within the range of KD
values (⬇10–100 nM) measured for erythromycin binding to ribosomes containing wild-type L22 or ⌬MKR-L22 (21–24). At the
highest concentrations of erythromycin tested, no translation by
⌬MKR ribosomes was detected (Fig. 1C Bottom). Erythromycin
also completely inhibited translation of another mRNA by L22-titin
and ⌬MKR-L22-titin ribosomes (data not shown). Thus, these
experiments are inconsistent with models in which the ⌬MKR
deletion in L22 allows the ribosome to function when erythromycin
is bound.
Erythromycin Sensitivity in Vivo. As anticipated from previous

studies, in liquid cultures of strains expressing only L22-titin or
⌬MKR-L22-titin, the mutation increased the erythromycin minimal inhibitory concentration (MIC) from ⬇125 to ⬇850 ⌴ (Fig.
2A, dashed lines), doubled the spiramycin MIC (⬇500 to ⬇1000
g/ml; data not shown), and quadrupled the tylosin MIC (⬇500 M
to ⬇2 mM; data not shown). E. coli strains containing plasmidborne L22 variants lacking the titin-fusion domain behaved simiAuthor contributions: S.D.M. designed research; S.D.M. performed research; S.D.M. contributed new reagents/analytic tools; S.D.M. analyzed data; and S.D.M. and R.T.S. wrote the
paper.
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Bacterial antibiotic resistance can occur by many mechanisms. An
intriguing class of mutants is resistant to macrolide antibiotics even
though these drugs still bind to their targets. For example, a
3-residue deletion (⌬MKR) in ribosomal protein L22 distorts a loop
that forms a constriction in the ribosome exit tunnel, apparently
allowing nascent-chain egress and translation in the presence of
bound macrolides. Here, however, we demonstrate that ⌬MKR and
wild-type ribosomes show comparable macrolide sensitivity in
vitro. In Escherichia coli, we find that this mutation reduces
antibiotic occupancy of the target site on ribosomes in a manner
largely dependent on the AcrAB-TolC efflux system. We propose a
model for antibiotic resistance in which ⌬MKR ribosomes alter the
translation of specific proteins, possibly via changes in programmed stalling, and modify the cell envelope in a manner that
lowers steady-state macrolide levels.
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Fig. 1. Ribosomal protein L22 and erythromycin inhibition of translation in vitro. (A) Crystal structure of L22 protein (green; M82K83R84 is shown in red), L4 protein
(blue), and 23S and 5S RNA (orange) from the 50S subunit of the E. coli ribosome (PDB entry 2AWB). The exit tunnel is visible through the center of the subunit. (B)
SDS-PAGE of proteins from purified ribosomes with wild-type L22, an L22-titin fusion, or a ⌬MKR L22-titin fusion. Wild-type L22 (12 kDa) is not resolved from other
ribosomal protein in the Left lane. The L22 fusion proteins are visible as separate bands (Center and Right lanes). (C) Autoradiograms of translation reactions containing
100 nM wild-type or ⌬MKR ribosomes and increasing amounts of erythromycin. (D) Integrated band intensities from the autoradiogram shown in the Top and Middle
of C are plotted as a percentage of the intensity of the band from the reaction without erythromycin. These data were fit to a quadratic binding equation to obtain
the inhibition constant (Ki).

larly (data not shown) as did strains with chromosomal alleles of
wild-type L22 or ⌬MKR L22 (2, 11–13). Although sufficiently high
concentrations of macrolides inhibited growth of both the L22-titin
and ⌬MKR-L22-titin strains, as expected from our results in vitro,
the differential macrolide sensitivity in vivo was not recapitulated
in the in vitro assays.
Efflux Pumps and Macrolide Resistance. Efflux pumps can dramatically alter the sensitivity of bacteria to antibiotics (2). For example,
phenylanine-arginine-␤-napthylamide (PA␤N) inhibits multidrug
efflux pumps and markedly lowers the MIC of erythromycin and
other antibiotics (25, 26). In strains expressing only L22-titin or only
⌬MKR-L22-titin, 30 g/ml PA␤N lowered the MIC for erythromycin ⬎20-fold (Fig. 2 A, solid lines) and the MICs for tylosin and
spiramycin ⬎10-fold (data not shown). Therefore, drug efflux plays
a significant role in determining the macrolide resistance of both
strains. In liquid culture, some growth of the L22-titin strain was
observed 2 h after addition of 200 M erythromycin (Fig. 2B). By
contrast, growth ceased almost immediately with 30 g/ml PA␤N
and 200 M erythromycin (Fig. 2B), suggesting that active erythromycin efflux normally delays growth inhibition. For the ⌬MKRL22-titin strain, 200 M erythromycin had little effect on growth in
the absence of the efflux inhibitor but caused rapid cessation of
growth in its presence (Fig. 2C).
18262 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0810357105

Erythromycin Inhibits L22-⌬MKR Ribosomes in Vivo. Is erythromycin

sensitivity of the ⌬MKR-L22-titin strain a consequence of drug
binding to the mutant ribosome or a different cellular target? To
answer this question, we used ErmC, which methylates A2058 in
23S rRNA and blocks erythromycin binding (27, 28). Constitutive
expression of ErmC allowed L22-titin or ⌬MKR-L22-titin strains to
grow in the presence of 200 M erythromycin and PA␤N (Fig. 2D).
The growth rates were approximately half those without erythromycin, which could be caused by incomplete ErmC methylation.
Indeed, consistent with a previous report (28), a primer-extension
assay, using reverse transcriptase showed that A2058 was methylated in only ⬇60% of the ribosomes (Fig. 2E). Because ErmCmediated resistance to erythromycin correlated approximately with
the extent of A2058 methylation, we conclude that erythromycin
inhibits growth of the ⌬MKR-L22-titin strain by occupying its
normal binding site in the exit tunnel of ⌬MKR ribosomes.
Erythromycin Binding to Ribosomes in Vivo. If ⌬MKR cells accumulated or retained less erythromycin than wild-type cells, then
⌬MKR ribosomes would appear to be more erthyromycin resistant
in vivo. Because erythromycin protects A2058 and A2059 in the 23S
rRNA of ribosomes from dimethyl sulfate (DMS) modification in
vitro (22, 29), we used DMS reactivity in vivo to monitor erythromycin binding. L22-titin or ⌬MKR-L22-titin cells were grown
without drug, with 200 M erythromycin, or with 200 M erythMoore and Sauer
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romycin and PA␤N, DMS was added, and total RNA was purified
and used for primer-extension reactions. The bands corresponding
to A2058/A2059 exhibited similar intensities in both strains grown
without erythromycin and showed reduced but comparable intensities in L22-titin or ⌬MKR-L22-titin cells treated with erythromycin and PA␤N (Fig. 3A). By contrast, A2058/A2059 were modified
to a greater extent in the ⌬MKR-L22-titin strain than in the
L22-titin strain after growth in erthyromycin alone (Fig. 3A). The
reactivity of A2062 did not change substantially with or without
erythromycin, allowing normalization of the A2058/A2059 intensities for quantitative comparisons (Fig. 3B). Irrespective of the L22
allele, A2058/A2059 reactivities were high in the absence of erythromycin and low in the presence of very high intracellular concentrations of erythromycin (mediated by PA␤N inhibition of efflux).
Importantly, A2058/A2059 reactivities were approximately twice as
high in ⌬MKR-L22-titin ribosomes than in L22-titin ribosomes
during growth in erthyromycin alone, supporting a model in which
the intracellular concentration of erythromycin is lower in the
⌬MKR cells.
Larger Deletions of the MKR Loop Do Not Confer Erythromycin
Resistance. Ribosomes containing L22 mutants with larger dele-

tions in the MKR loop appear to be functional in merodiploid
strains, because they are found with wild-type ribosomes in polyMoore and Sauer

somes (30). To test whether these larger deletions allowed ribosome
function in the presence of erythromycin, we constructed strains
expressing just L22-titin variants missing residues 85–95 (⌬loop1) or
residues 82–100 (⌬loop2) (Fig. 4A). In growth-rate studies, the
doubling times were 34 min (L22-titin), 53 min (⌬MKR-L22-titin),
57 min (⌬loop1-L22-titin), and 62 min (⌬loop2-L22-titin) (data not
shown). Thus, all of the deletions allow bacterial growth but with
significant growth defects. The ⌬loop1 and ⌬loop2 strains did not
grow on plates with 200 M erythromycin (Fig. 4B) and had
erythromycin MICs in liquid culture of ⬇125 M and ⬇150 M,
respectively (data not shown). Thus, partial or complete removal of
the MKR loop from the narrow constriction in the exit tunnel is not
sufficient to confer significant increases in erythromycin resistance.
Because strains with the extended loop mutants grew more slowly
than the ⌬MKR mutant, these results also show that L22-mediated
slowing of the growth rate is not sufficient to confer enhanced
macrolide resistance. We also constructed a strain in which
M82K83R84 of L22 was replaced with A82A83A84. This strain grew as
well as wild type in the absence of erythromycin and was equally
sensitive to the antibiotic (data not shown). Thus, the chemical
identity of the side chains at these residue positions is unrelated to
the resistance phenotype caused by the ⌬MKR deletion.
acrAB-tolC System and ⌬MKR Macrolide Resistance. In E. coli, the

AcrAB-TolC efflux system is primarily responsible for resistance to
PNAS 兩 November 25, 2008 兩 vol. 105 兩 no. 47 兩 18263
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Fig. 2. Erythromycin sensitivity increases when drug efflux is blocked. (A) Erythromycin resistance of strains containing wild-type L22-titin (triangles) or ⌬MKR L22-titin
(circles). The turbidity (600 nm) of 16 h cultures grown at 37 °C in the presence of erythromycin (dashed lines) or erythromycin and 30 g/ml PA␤N (solid lines) is plotted
as a percentage of the value of a culture grown without drug. (B) Growth at 37 °C of cultures containing the wild-type L22-titin fusion in the absence of erythromycin
(open circles), after addition of 200 M erythromycin (filled circles), or after addition of 200 M erythromycin and 30 g/ml PA␤N (filled triangles). (C) Growth of cultures
containing the ⌬MKR mutation in L22 with the same symbols as in B. (D) Strains containing wild-type (circles) or ⌬MKR L22 (filled circles) and an induced ermC gene
were grown in medium with 30 g/ml PA␤N to early log phase and erythromycin was added to 200 M at the time indicated by the arrows. (E) ErmC methylation of
A2058 in 23S RNA assayed by primer extension. An oligonucleotide complementary to 23S rRNA bases 2066 –2102 was used to prime a reverse-transcription reaction
containing dideoxy-ATP and RNA purified from strains containing wild-type or ⌬MKR L22-titin fusions grown with or without induction of ermC. Reaction products
were electrophoresed on a urea-acrylamide gel. In the presence of template RNA, reverse transcription proceeded until blocked by ErmC-mediated methylation of
A2058 or until incorporation of dideoxy-ATP at the position corresponding to U2041.
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Fig. 3. Reduced erythromycin binding to ribosomes with ⌬MKR L22 in vivo.
Cultures were treated with dimethyl sulfate (DMS), reactions were quenched,
and total RNA was purified and used in primer-extension assays to detect base
modifications near the erythromycin-binding site in 23S rRNA. (A) Gel of
primer-extension products from the following RNA templates: (Lane 1) NonDMS-treated ErmC-modified template (product terminates at the position
corresponding to A2058). (Lanes 2 and 3) Templates from cultures grown
without erythromycin. (Lanes 4 and 5) Templates from cultures grown with
200 M erythromycin. (Lanes 6 and 7) Templates from cultures grown with 200
M erythromycin and 30 g/ml PA␤N. (B) Plots of the ratio of band intensities
corresponding to A2058 (filled bars) or A2059 (hatched bars) in A divided by
the intensity of A2062.

low levels of erythromycin and a variety of other toxic compounds
(31–32). To determine whether this system was responsible for the
increased resistance conferred by the ⌬MKR mutation, we deleted
either the AcrA/AcrB or TolC ORFs and assayed resistance to
erythromycin. Deletion of either tolC or acrAB abolished much of
the difference in erythromycin resistance between strains expressing L22-titin or ⌬MKR-L22-titin and substantially increased the
sensitivity of both strains (Fig. 5 A and B). Therefore, increased
drug efflux mediated by AcrAB-TolC appears to be largely responsible for the increased erythromycin resistance conferred by the
⌬MKR mutation. The tolC deletion reduced the difference in
erythromycin sensitivity between the wild-type and ⌬MKR strains
to a greater extent than the acrAB deletion. This result can be
rationalized because several TolC-dependent efflux pumps in addition to ArcAB-TolC have also been shown to plays roles in
erythromycin resistance (32, 34).
Discussion
The discovery that bacterial resistance to erythromycin can be
caused by mutations in ribosomal proteins was first reported in
1967, and the ⌬MKR deletion in protein L22 was subsequently
shown to cause this phenotype (8, 11, 12). Since these initial
observations, consensus molecular mechanisms for macrolide inhibition of translation and for the effects of the ⌬MKR mutation
have emerged from biochemical and structural studies (3, 4, 7, 18,
19). According to the exit-tunnel blockade/bypass model, macrolides sterically block peptide elongation during translation by bind18264 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0810357105

plate with 200 µM
erythromycin
Fig. 4. Extended L22 loop deletions. (A) Ribbon drawings of E. coli L22 with the
M82-K83-R84 residues marked in red (PDB 2AWB). The ⌬loop1 and ⌬loop2 deletions remove residues 85–95 and 82–100, respectively. (B) Growth of strains on a
plate containing 200 M erythromycin.

ing in the exit tunnel of the large ribosomal subunit, with the ⌬MKR
deletion serving to relieve this blockade by providing additional
space for the nascent chain to bypass the drug and enter the exit
tunnel.
Our results disprove the prevailing ⌬MKR bypass model (18, 19),
which predicts that ribosomes harboring the L22 ⌬MKR deletion
should be active in the presence of bound macrolides. By contrast,
we find that erythromycin inhibits translation by ⌬MKR ribosomes
in vitro, with the mutant ribosomes being as sensitive to inhibition
as wild-type ribosomes. In the cell, we find that ⌬MKR ribosomes
are also sensitive to macrolides added at sufficiently high concentrations, in agreement with previous studies (12). In E. coli expressing ⌬MKR-L22-titin, the MIC for erythromycin is 850 M, but this
value drops to ⬇10 M when PA␤N, an inhibitor of efflux pumps
is also present. Similarly, mutations that inactivate the AcrAB-TolC
efflux system reduce the MIC for erythromycin to 5–10 M for
⌬MKR strains. These inhibitory effects are caused by macrolide
binding to the site near the exit tunnel of ⌬MKR ribosomes,
because ErmC methylation of a base within this site alleviates
inhibition both in vitro (data not shown) and in vivo. These results
do not support models that rely on macrolide-bound ⌬MKR
ribosomes functioning better than macrolide-bound wild-type
ribosomes.
Macrolide concentrations appear to be lower in ⌬MKR strains
than in wild-type strains. For example, when ⌬MKR or wild-type
cells are grown in 200 M erythromycin, footprinting experiments
show lower occupancy of the macrolide-binding site in ⌬MKR
ribosomes, but similar occupancy in the presence of an efflux
inhibitor. This result is unlikely to arise from differences in affinity,
because we find that both types of ribosomes show similar sensitivity
to erythromycin inhibition in vitro and previous studies show that
erythromycin binds ⌬MKR ribosomes similarly to wild-type ribosomes (8, 12). Moreover, small differences in the affinity of
erythromycin for wild-type and ⌬MKR ribosomes in the cell should
have no appreciable effect on occupancy, because near stoichiometric binding would be expected in both cases because the
Moore and Sauer

the regulatory mechanisms by which these compounds are sensed
by the cell (40). Because erythromycin must enter and cross the
inner membrane to gain access to ribosomes, a delay in this step
could result in the efflux pumps being more effective at shedding
the drug in the ⌬MKR strain, which would not necessarily require
increased pump levels.
Although the mechanism by which the ⌬MKR mutation increases macrolide resistance remains to be determined, it seems
plausible that L22-mediated ribosome stalling plays a role in
determining the balance of cell envelope components, which, in
turn, affects macrolide resistance by altering the efficiency of efflux
pumps. Moreover, given that the antibiotic resistance of wild-type
and ⌬MKR strains often changed in parallel when efflux systems
were perturbed, it seems likely that the ⌬MKR mutation simply
enhances a ribosome-mediated defense mechanism against antibiotics that also occurs in wild-type cells.
We note that L22 mutations can cause macrolide resistance in
Gram-positive and Gram-negative bacteria (2). Although Grampositive strains lack TolC-mediated efflux systems, they do contain
numerous membrane efflux pumps capable of transporting a wide
variety of compounds including macrolides (2). Moreover, synergistic relationships between L22-mediated antibiotic resistance and
efflux systems have been reported in strains of Haemophilus and
Campylobacter (41, 42). Thus, the connection between L22 function
and drug efflux seems to be highly conserved. Our experiments
show that ⌬MKR ribosomes are not inherently resistant to macrolides and support a new model in which changes in translation
alter bacterial physiology and reduce macrolide accumulation.
Because wild-type and ⌬MKR strains are efficiently inhibited by
low concentrations of macrolides when drug efflux is blocked,
combination therapies, using macrolides and efflux inhibitors may
be an appealing antibacterial strategy that precludes many normal
routes to drug resistance.
Experimental Procedures

intracellular concentration of ribosomes exceeds the KD for erythromycin binding by 100-fold or more (35). Two mechanisms could
potentially give rise to reduced drug concentration in the ⌬MKR
strain: (i) a factor sequesters or destroys the antibiotic; or (ii)
cellular uptake of the drug is reduced or efflux is increased.
Although either of these mechanisms are feasible, we favor the
second possibility, which is consistent with our findings that blocking efflux with PA␤N makes cells more sensitive to erythromycin
and deleting either the AcrA/AcrB or TolC components of the
AcrAB-TolC efflux pump reduces the erythromycin resistance of
a strain with ⌬MKR-L22-titin ribosomes compared with a strain
with L22-titin ribosomes.
The ⌬MKR mutation is known to affect translation of certain
mRNAs by reducing programmed ribosome stalling (36, 37). How
might ⌬MKR-linked translational changes affect macrolide uptake
or efflux? It is possible that AcrAB and/or TolC activities are
increased through direct effects on translation of these proteins or
indirect effects on translation of a regulator. However, preliminary
experiments, using Western blot analysis with anti-AcrA and antiTolC antibodies did not reveal up-regulation of these proteins in the
⌬MKR strain (data not shown). Moreover, our ⌬MKR strain did
not show enhanced resistance to SDS or ethidium bromide (data
not shown), which are also pumped from the cell by the AcrABTolC system (38, 39), although this result could be complicated by
Moore and Sauer

Strains and Plasmids. L22 fusions containing an N-terminal His6 tag and a
C-terminal titin-I27-ssrA domain were encoded on plasmid pS10 and maintained
in clpX⫺, clpA⫺, rna⫺ cells with a deletion of the chromosomal S10 operon (20).
We confirmed that the macrolide resistance mediated by the L22 ⌬MKR mutation
was not altered in clpX⫹, clpA⫹, rna⫹ strains or when the C-terminal I27-ssrA
fusion was omitted (data not shown). The tolC⫺ strains were constructed by P1
transducing tolC::kan from strain JW5503–1 of the Keio collection (43) into strain
SM1090 (X90, clpX⫺, clpA⫺, rna⫺), removing the kan marker with FLP recombinase (44), transforming with either pS10-H6-L22WT-I27-ssrA or pS10-H6-L22⌬MKRI27-ssrA, and then deleting the chromosomal S10 operon (20). The acrAB⫺ strains
were constructed by replacing the acrAB ORF with a PCR product containing the
cat gene, using the recombination plasmid pSIM-5 (45), and then transducing the
cat gene by selection on chloramphenicol into strains SM1145 (wild-type L22) or
SM1211 (L22 ⌬MKR) (20). All constructs were verified using diagnostic PCR and
the wild-type, ⌬MKR, ⌬loop1, and ⌬loop2 L22 fusions constructs were verified as
the only copies of L22 genes in the cell by Southern blot analysis with a probe
complementary to the antisense strand of the rplV gene (20). A plasmid containing only the ORF of the ermC gene from Bacillus subtilis under control of an
arabinose-inducible promoter (pBAD24-ermC) was a gift from C. Hayes (University of California, Santa Barbara, CA) and was introduced into wild-type and
⌬MKR strains and grown in the presence of 0.2% arabinose for induction.
Antibiotics, Culture Growth, and MIC Determination. Antibiotics and PA␤N were
purchased from SIGMA-Aldrich. Stocks of erythromycin were prepared in ethanol, and the concentration was determined in 10 mM bis-Tris (pH 6.5), using an
extinction coefficient at 298 nm of 25.7 M⫺1䡠cm⫺1. MICs for antibiotics were
determined in Luria–Bertani broth supplemented with 1⫻‘‘Mops mixture’’ (pH
7.2, Teknova), using 150 L of cultures in 96-well plates containing 1,000 logphase colony-forming units per well and grown with agitation for 16 h at 37 °C.
Culture densities were determined by measuring the turbidity at 600 nm.
Biochemical Assays. Purification of ribosomes and rRNA from log-phase cultures
and reverse-transcriptase extension of a 5⬘-TCAATGTTCAGTGTCAAGCTATAGTAAAGGTTCACG-3⬘ primer complementary to residues 2066 –2101 of E. coli 23S
rRNA were performed as described in ref. 20. Coupled transcription/translation
assays were performed as described in ref. 20 by adding purified ribosomes to
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Fig. 5. Contribution of AcrAB-TolC to erythromycin resistance. The TolC or
AcrA/AcrB components of the AcrAB-TolC efflux pump were deleted from strains
with wild-type or ⌬MKR ribosomes. (A) Erythromycin resistance of cells lacking
tolC with wild-type (triangles) or ⌬MKR (circles) ribosomes. (B) Erythromycin
resistance of cells lacking acrA/acrB with wild-type (triangles) or ⌬MKR (circles)
ribosomes. Inhibition plots of tolC⫹ acrAB⫹ cells are shown for comparison
(dashed lines).

complete a ribosome-free translation extract. Erythromycin was then added to
desired concentrations, the mixtures were incubated at room temperature for 15
min, and reactions were started by adding a plasmid encoding the SspB and
␤-lactamase proteins under control of a T7 promoter. After 1 h of transcription/
translation at 37 °C, reactions were stopped and 14C-labeled proteins were visualized using SDS-PAGE and autoradiography. Some experiments were performed
using a transcription template encoding a variant of the E. coli rbsK gene. These
translation assays produced 14C-labeled proteins in a linear fashion for ⬎120 min,
and thus the intensity of the product bands at 60 min is a reasonable estimate of
the translation rate. Inhibition constants (Ki) were obtained by fitting the erythromycin (E) dependence of ribosome (R) inhibition to the equation activity ⫽
max䡠(1 ⫺ ((([Etotal] ⫹ [Rtotal] ⫹ Ki) ⫺ SQRT(([Etotal] ⫹ [Rtotal] ⫹ Ki)2) ⫺
4䡠[Etotal]䡠[Rtotal]))/(2䡠[Rtotal]))).
DMS modification of ribosomes in vivo was performed similarly to a published
protocol (46). Cultures of wild-type and ⌬MKR cells were grown in LB broth with
shaking at 37 °C until early log phase and erythromycin was then added to 1
aliquot of each culture. Growth was continued for 2 h and cells were chilled on

ice, harvested, and resuspended at equal cell densities (⬇1.2 ⫻ 109 cfu per
milliliter) in fresh medium with or without erythromycin. Aliquots of each culture
were then placed in clean tubes in a 37 °C water bath and PA␤N was added to 30
g/ml in 1 sample of each strain containing erythromycin. After 10 min of
preincubation, DMS solution (freshly diluted 1/6 in ethanol) was added (⬇50 mM
final) to each culture, and the cultures were incubated with shaking for an
additional 15 min. Reactions were stopped by diluting an aliquot of each culture
20-fold into ice-cold stop solution (100 mM Tris䡠Cl (pH 7.5), 0.5 M 2-mercaptoethanol, 50 mM NaCl, 2 mM MgOAc) and mixing rapidly. Cells were then harvested at 4 °C, washed twice with ice-cold buffer (50 mM Tris䡠Cl (pH 7.5), 50 mM
NaCl, 2 mM MgOAc), and resuspended in lysis buffer (B-Per II (Pierce) supplemented with 2 mM MgOAc, 0.5 mM CaCl2, 10 units/ml DNase I (Roche), and 0.1
mg/ml lysozyme). After lysis, total RNA was purified using acidic phenol/
chloroform extraction and alcohol precipitation (20).

1. Vester B, Douthwaite S (2001) Macrolide resistance conferred by base substitutions in 23S
rRNA. Antimicrob Agents Chemother 45:1–12.
2. Roberts MC (2008) Update on macrolide-lincosamide-streptogramin, ketolide, and oxazolidinone resistance genes. FEMS Microbiol Lett 282:147–159.
3. Schlünzen F, et al. (2001) Structural basis for the interaction of antibiotics with the peptidyl
transferase centre in eubacteria. Nature 413:814 – 821.
4. Tu D, Blaha G, Moore PB, Steitz TA (2005) Structures of MLSBK antibiotics bound to
mutated large ribosomal subunits provide a structural explanation for resistance. Cell
121:257–270.
5. Contreras A, Vázquez D (1977) Cooperative and antagonistic interactions of peptidyltRNA and antibiotics with bacterial ribosomes. Eur J Biochem 74:539 –547.
6. Andersson S, Kurland CG (1987) Elongating ribosomes in vivo are refractory to erythromycin. Biochimie 69:901–904.
7. Tenson T, Lovmar M, Ehrenberg M (2003) The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol
Biol 330:1005–1014.
8. Wittmann HG, et al. (1973) Biochemical and genetic studies on two different types of
erythromycin resistant mutants of Escherichia coli with altered ribosomal proteins. Mol
Gen Genet 127:175–189.
9. Douthwaite S, Powers T, Lee JY, Noller HF (1989) Defining the structural requirements for
a helix in 23 S ribosomal RNA that confers erythromycin resistance. J Mol Biol 209:655– 665.
10. Zaman S, Fitzpatrick M, Lindahl L, Zengel J (2007) Novel mutations in ribosomal proteins
L4 and L22 that confer erythromycin resistance in Escherichia coli. Mol Microbiol 66:1039 –
1050.
11. Apirion D (1967) Three genes that affect Escherichia coli ribosomes. J Mol Biol 30:255–275.
12. Chittum HS, Champney WS (1994) Ribosomal protein gene sequence changes in erythromycin-resistant mutants of Escherichia coli. J Bacteriol 176:6192– 6198.
13. Gregory ST, Dahlberg AE (1999) Erythromycin resistance mutations in ribosomal proteins
L22 and L4 perturb the higher order structure of 23 S ribosomal RNA. J Mol Biol 289:827–
834.
14. Clark C, et al. (2002) In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin. Antimicrob
Agents Chemother 46:2956 –2962.
15. Pardo D, Rosset R (1977) Properties of ribosomes from erythromycin resistant mutants of
Escherichia coli. Mol Gen Genet 156:267–271.
16. Schuwirth BS, et al. (2005) Structures of the bacterial ribosome at 3.5 A resolution. Science
310:827– 834.
17. Voss NR, Gerstein M, Steitz TA, Moore PB (2006) The geometry of the ribosomal polypeptide exit tunnel. J Mol Biol 360:893–906.
18. Gabashvili IS, et al. (2001) The polypeptide tunnel system in the ribosome and its gating in
erythromycin resistance mutants of L4 and L22. Mol Cell 8:181–188.
19. Davydova N, Streltsov V, Wilce M, Liljas A, Garber M (2002) L22 ribosomal protein and
effect of its mutation on ribosome resistance to erythromycin. J Mol Biol 322:635– 644.
20. Moore SD, Baker TA, Sauer RT (2008) Forced extraction of targeted components from
complex macromolecular assemblies. Proc Natl Acad Sci USA 105:11685–11690.
21. Pestka S (1974) Binding of [14C]erythromycin to Escherichia coli ribosomes. Antimicrob
Agents Chemother 6:474 – 478.
22. Douthwaite S, Aagaard C (1993) Erythromycin binding is reduced in ribosomes with
conformational alterations in the 23 S rRNA peptidyl transferase loop. J Mol Biol 232:725–
731.
23. Lovmar M, Tenson T, Ehrenberg M (2004) Kinetics of macrolide action: The josamycin and
erythromycin cases. J Biol Chem 279:53506 –53515.
24. Petropoulos AD, Kouvela EC, Dinos GP, Kalpaxis DL (2008) Stepwise binding of tylosin and
erythromycin to Escherichia coli ribosomes, characterized by kinetic and footprinting
analysis. J Biol Chem 283:4756 – 4765.
25. Lomovskaya O, et al. (2001) Identification and characterization of inhibitors of multidrug
resistance efflux pumps in Pseudomonas aeruginosa: Novel agents for combination therapy. Antimicrob Agents Chemother 45:105–116.

26. Chollet R, Chevalier J, Bryskier A, Pagès JM (2004) The AcrAB-TolC pump is involved in
macrolide resistance but not in telithromycin efflux in Enterobacter aerogenes and Escherichia coli. Antimicrob Agents Chemother 48:3621–3624.
27. Skinner R, Cundliffe E, Schmidt FJ (1983) Site of action of a ribosomal RNA methylase
responsible for resistance to erythromycin and other antibiotics. J Biol Chem 258:12702–
12706.
28. Denoya CD, Dubnau D (1987) Site and substrate specificity of the ermC 23S rRNA methyltransferase. J Bacteriol 169:3857–3860.
29. Moazed D, Noller HF (1987) Chloramphenicol, erythromycin, carbomycin and vernamycin
B protect overlapping sites in the peptidyl transferase region of 23S ribosomal RNA.
Biochimie 69:879 – 884.
30. Zengel JM, Jerauld A, Walker A, Wahl MC, Lindahl L (2003) The extended loops of
ribosomal proteins L4 and L22 are not required for ribosome assembly or L4-mediated
autogenous control. RNA 9:1188 –1197.
31. Nikaido H (1998) Multiple antibiotic resistance and efflux. Curr Opin Microbiol 1:516 –
523.
32. Kobayashi N, Nishino K, Yamaguchi A (2001) Novel macrolide-specific ABC-type efflux
transporter in Escherichia coli. J Bacteriol 183:5639 –5644.
33. Jellen-Ritter AS, Kern WV (2001) Enhanced expression of the multidrug efflux pumps
AcrAB and AcrEF associated with insertion element transposition in Escherichia coli
mutants Selected with a fluoroquinolone. Antimicrob Agents Chemother 45:1467–
1472.
34. Nishino K, Senda Y, Yamaguchi A (2008) The AraC-family regulator GadX enhances
multidrug resistance in Escherichia coli by activating expression of mdtEF multidrug efflux
genes. J Infect Chemother 14:23–29.
35. Dennis PP, Bremer H (1974) Macromolecular composition during steady-state growth of
Escherichia coli B-r. J Bacteriol 119:270 –281.
36. Nakatogawa H, Ito K (2002) The ribosomal exit tunnel functions as a discriminating gate.
Cell 108:629 – 636.
37. Vazquez-Laslop N, Thum C, Mankin AS (2008) Molecular mechanism of drug-dependent
ribosome stalling. Mol Cell 30:190 –202.
38. Otsuji N, Soejima T, Maki S, Shinagawa H (1982) Cloning of colicin E1 tolerant tolC (mtcB)
gene of Escherichia coli K12 and identification of its gene product. Mol Gen Genet
187:30 –36.
39. Kawabe T, Fujihira E, Yamaguchi A (2000) Molecular construction of a multidrug exporter
system, AcrAB: Molecular interaction between AcrA and AcrB, and cleavage of the
N-terminal signal sequence of AcrA. J Biochem 128:195–200.
40. Rosenberg EY, Bertenthal D, Nilles ML, Bertrand KP, Nikaido H (2003) Bile salts and fatty
acids induce the expression of Escherichia coli AcrAB multidrug efflux pump through their
interaction with Rob regulatory protein. Mol Microbiol 48:1609 –1619.
41. Peric M, et al. (2004) Inability of L22 ribosomal protein alteration to increase macrolide
MICs in the absence of efflux mechanism in Haemophilus influenzae HMC-S. J Antimicrob
Chemother 54:393– 400.
42. Cagliero C, Mouline C, Cloeckaert A, Payot S (2006) Synergy between efflux pump CmeABC
and modifications in ribosomal proteins L4 and L22 in conferring macrolide resistance in
Campylobacter jejuni and Campylobacter coli. Antimicrob Agents Chemother 50:3893–
3896.
43. Baba T, et al. (2006) Construction of Escherichia coli K-12 in-frame, single-gene knockout
mutants: The Keio collection. Mol Syst Biol 2:1–11.
44. Datsenko KA, Wanner BL (2000) One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 97:6640 – 6645.
45. Datta S, Costantino N, Court DL (2006) A set of recombineering plasmids for gram-negative
bacteria. Gene 379:109 –115.
46. Moazed D, Robertson JM, Noller HF (1988) Interaction of elongation factors EF-G and
EF-Tu with a conserved loop in 23S RNA. Nature 334:362–364.

18266 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0810357105

ACKNOWLEDGMENTS. We thank K. Griffith, A. Grossman, and R. Britton for
helpful discussions and C. Hayes for materials and discussions. This work was
supported by National Institutes of Health Grants AI-15706 and AI-16892.

Moore and Sauer

